ritonavir
Ligand Summary
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease. Inhibition of HIV protease renders the enzyme incapable of processing the Gag-Pol polyprotein precursor which leads to production of non-infectious immature HIV particles. Nirmatrelvir plus ritonavir (Paxlovid) has been approved for the treatment and post-exposure prophylaxis of coronavirus disease 2019 (COVID-19).
UNII: O3J8G9O825
PubChem: 392622
Guide to Pharmacology: 8804
ChEMBL: CHEMBL163
DrugCentral: 2391
LyCHI: N7SKXRKBPY6M
Target Activities
20 Activities
Items per page:
10
1 – 10 of 20
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
Ki | ||||||
Ki | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Ki | ||||||
IC50 | ||||||
IC50 | ||||||